JP2024023290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023290A5 JP2024023290A5 JP2023193160A JP2023193160A JP2024023290A5 JP 2024023290 A5 JP2024023290 A5 JP 2024023290A5 JP 2023193160 A JP2023193160 A JP 2023193160A JP 2023193160 A JP2023193160 A JP 2023193160A JP 2024023290 A5 JP2024023290 A5 JP 2024023290A5
- Authority
- JP
- Japan
- Prior art keywords
- ido1
- inhibitor
- composition
- tryptophan
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 6
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical group C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 claims 5
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 5
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 5
- 229940043367 IDO1 inhibitor Drugs 0.000 claims 3
- PRWSIEBRGXYXAJ-UHFFFAOYSA-N GSK2656157 Chemical compound CC1=CC=CC(CC(=O)N2C3=C(C(=C(C=4C5=C(N)N=CN=C5N(C)C=4)C=C3)F)CC2)=N1 PRWSIEBRGXYXAJ-UHFFFAOYSA-N 0.000 claims 2
- 229940123090 PERK inhibitor Drugs 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 claims 2
- GZSOKPMDWVRVMG-UHFFFAOYSA-N 2-[n-(2-bromoethyl)-2,4-dinitro-6-(2-phosphonooxyethylcarbamoyl)anilino]ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCN(CCBr)C1=C(C(=O)NCCOP(O)(O)=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O GZSOKPMDWVRVMG-UHFFFAOYSA-N 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- MUJMYVFVAWFUJL-SNAWJCMRSA-O [(e)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium Chemical compound CN1C=NC([N+]([O-])=O)=C1C[N+](C)(C)C\C=C\C(=O)NC(N=CC1=NC=N2)=CC1=C2NC1=CC=C(Cl)C(Br)=C1 MUJMYVFVAWFUJL-SNAWJCMRSA-O 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- UGJWRPJDTDGERK-UHFFFAOYSA-N evofosfamide Chemical compound CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N+]([O-])=O UGJWRPJDTDGERK-UHFFFAOYSA-N 0.000 claims 1
- 229950009988 evofosfamide Drugs 0.000 claims 1
- SIXVRXARNAVBTC-UHFFFAOYSA-N gsk2606414 Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 SIXVRXARNAVBTC-UHFFFAOYSA-N 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 229950009034 indoximod Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558573P | 2017-09-14 | 2017-09-14 | |
| US62/558,573 | 2017-09-14 | ||
| JP2020515740A JP2020534289A (ja) | 2017-09-14 | 2018-09-14 | がんの治療のための方法および組成物 |
| PCT/US2018/051088 WO2019055786A1 (en) | 2017-09-14 | 2018-09-14 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515740A Division JP2020534289A (ja) | 2017-09-14 | 2018-09-14 | がんの治療のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024023290A JP2024023290A (ja) | 2024-02-21 |
| JP2024023290A5 true JP2024023290A5 (https=) | 2024-06-14 |
Family
ID=65724068
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515740A Pending JP2020534289A (ja) | 2017-09-14 | 2018-09-14 | がんの治療のための方法および組成物 |
| JP2023193160A Pending JP2024023290A (ja) | 2017-09-14 | 2023-11-13 | がんの治療のための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515740A Pending JP2020534289A (ja) | 2017-09-14 | 2018-09-14 | がんの治療のための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200261414A1 (https=) |
| EP (2) | EP4176876A1 (https=) |
| JP (2) | JP2020534289A (https=) |
| ES (1) | ES2935729T3 (https=) |
| WO (1) | WO2019055786A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240084002A1 (en) * | 2020-12-07 | 2024-03-14 | Lankenau Institute For Medical Research | Methods and compositions utilizing ido1-dependent vascularizing cells for the treatment of pathological conditions involving neovascularization |
| WO2023025312A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| CN117651548B (zh) | 2021-08-27 | 2026-03-03 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| CN119384281A (zh) | 2022-04-15 | 2025-01-28 | 深圳艾欣达伟医药科技有限公司 | 使用th-302单药或联用parp抑制剂治疗癌症的方法 |
| CN119233822A (zh) | 2022-05-23 | 2024-12-31 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| KR20250160163A (ko) | 2023-02-27 | 2025-11-11 | 아센타위츠 파마슈티컬즈 리미티드 | 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법 |
| WO2025026214A1 (zh) | 2023-07-28 | 2025-02-06 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变或缺陷阴性癌症、肿瘤患者 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| US7714139B2 (en) | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| ZA200507752B (en) * | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US7705022B2 (en) | 2005-10-27 | 2010-04-27 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080146624A1 (en) | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| WO2008036643A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008058178A1 (en) | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CA2706378C (en) | 2007-11-20 | 2017-09-12 | Lankenau Institute For Medical Research | Disulfide chemotherapeutic agents and methods of use thereof |
| JP5465720B2 (ja) | 2008-07-08 | 2014-04-09 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| AU2013204313C1 (en) * | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
| WO2016090174A1 (en) * | 2014-12-03 | 2016-06-09 | Auckland Uniservices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
| EP4659747A2 (en) | 2015-07-24 | 2025-12-10 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
| EP3359150A4 (en) * | 2015-10-05 | 2019-11-06 | Calithera Biosciences, Inc. | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS |
| US20190241573A1 (en) * | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
-
2018
- 2018-09-14 JP JP2020515740A patent/JP2020534289A/ja active Pending
- 2018-09-14 US US16/647,260 patent/US20200261414A1/en not_active Abandoned
- 2018-09-14 ES ES18856836T patent/ES2935729T3/es active Active
- 2018-09-14 WO PCT/US2018/051088 patent/WO2019055786A1/en not_active Ceased
- 2018-09-14 EP EP22199365.2A patent/EP4176876A1/en active Pending
- 2018-09-14 EP EP18856836.4A patent/EP3681498B1/en active Active
-
2023
- 2023-11-13 JP JP2023193160A patent/JP2024023290A/ja active Pending
- 2023-12-11 US US18/535,111 patent/US20240374566A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023290A5 (https=) | ||
| JP2017536092A5 (https=) | ||
| Siuda et al. | Transcriptional regulation of Nox4 by histone deacetylases in human endothelial cells | |
| Locatelli et al. | Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement | |
| JP2011516565A5 (https=) | ||
| Yang et al. | Overexpression of carbonic anhydrase IX induces cell motility by activating matrix metalloproteinase-9 in human oral squamous cell carcinoma cells | |
| EP2451795B1 (en) | Compositions and uses for enhancing virus production | |
| JP2021530451A5 (https=) | ||
| JP2014508720A5 (https=) | ||
| CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
| JP2013537423A5 (https=) | ||
| JP2014526450A5 (https=) | ||
| RU2012142180A (ru) | Ингибиторы катехол-о-метилтрансферазы и их применение для лечения психотических расстройств | |
| US8765797B2 (en) | TG2 inhibitors and uses thereof | |
| JP2017518334A5 (https=) | ||
| JP2014505107A5 (https=) | ||
| JP5149177B2 (ja) | 増殖性疾患の治療のための、チューブリンポリマー化の１，２，３−トリアゾール系抑制剤 | |
| JP2023530316A5 (https=) | ||
| US20210023077A1 (en) | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor | |
| JP2007530598A (ja) | マクロファージ遊走阻害因子の阻害に関する、化合物、組成物、作製プロセス、および使用方法 | |
| US9457045B2 (en) | Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer | |
| Hermann | Viral RNA targets and their small molecule ligands | |
| US20130018086A1 (en) | Sirnas targeting exon 10 of pyruvate kinase m2 | |
| JP2024546569A5 (https=) | ||
| JP2017502278A5 (https=) |